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Abstract
Background: Host genetic factors may play a role in susceptibility and resistance to SARS
associated coronavirus (SARS-CoV) infection. The study was carried out to investigate the
association between the genetic polymorphisms of 2',5'-oligoadenylate synthetase 1 (OAS1) gene
as well as myxovirus resistance 1 (MxA) gene and susceptibility to SARS in Chinese Han population.
Methods: A hospital-based case-control study was conducted. A collective of 66 SARS cases and
64 close contact uninfected controls were enrolled in this study. End point real time polymerase
chain reaction (PCR) and PCR-based Restriction Fragment Length Polymorphism (RFLP) analysis
were used to detect the single nucleic polymorphisms (SNPs) in OAS1 and MxA genes. Information
on other factors associated with SARS infection was collected using a pre-tested questionnaire.
Univariate and multivariate logistic analyses were conducted.
Results: One polymorphism in the 3'-untranslated region (3'-UTR) of the OAS1 gene was
associated with SARS infection. Compared to AA genotype, AG and GG genotypes were found
associated with a protective effect on SARS infection with ORs (95% CI) of 0.42 (0.20~0.89) and
0.30 (0.09~0.97), respectively. Also, a GT genotype at position 88 in the MxA gene promoter was
associated with increased susceptibility to SARS infection compared to a GG genotype (OR = 3.06,
95% CI: 1.25~7.50). The associations of AG genotype in OAS1 and GT genotype in MxA remained
significant in multivariate analyses after adjusting for SARS protective measures (OR = 0.38, 95% CI:
0.14~0.98 and OR = 3.22, 95% CI: 1.13~9.18, respectively).
Conclusion: SNPs in the OAS1 3'-UTR and MxA promoter region appear associated with host
susceptibility to SARS in Chinese Han population.
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Background
Severe acute respiratory syndrome (SARS) is an emerging
infectious disease caused by a novel positive-stranded
RNA virus, termed SARS-CoV [1]. The global outbreak of
SARS has killed 774 and infected more than 8098 people
in 29 countries and regions, as reported by WHO [2]. In
Beijing, more than 2523 cases and 181 deaths occurred
including health care workers and family members who
had closely contacted with SARS patients [3]. It was
noticed that despite similar levels of exposure to the SARS-
CoV some people were infected while others were still free
from infection, suggesting a role of host genetic factors in
susceptibility to SARS-CoV infection [4]. Human-Leuko-
cyte-Antigen Class I and Class II Genotypes were previ-
ously reported to be associated with the development of
SARS [5,6]. The polymorphism of angiotensin converting
enzyme 1 gene was supposed to be involved in the pro-
gression of the disease [7].
Resent study showed that type I interferons (IFN-c/d)
could inhibit SARS-CoV replication both in vivo and in
vitro [8-10]. Type I interferons induce numerous proteins
with antiviral activities, including 2'-5' oligoadenylate
synthetase 1 (OAS1) and myxovirus resistance 1 (MxA).
OAS1 protein can bind double-stranded RNA and polym-
erize ATP into PPP (A2'P5'A) N oligomers, which activate
the latent RNAse L that, when activated, cleave single-
stranded RNAs [11]. MxA protein belongs to the dynamin
family and shows activity against several viruses [12-14].
However, the precise mechanism of antiviral action has
not been elucidated. Host genetic factors that influence
antiviral effects of interferons were well demonstrated in
viral hepatitis, especially of hepatitis C virus infection
[15]. It was reported that the polymorphisms at position
347 in the 3'-untranslated region (3'-UTR) of the OAS1
gene and at position 88 in the MxA gene promoter region
seemed associated with hepatitis C virus infection [16].
The polymorphisms of these two genes that might affect
the susceptibility to SARS were reported in Vietnamese
population [17]. The G allele frequencies of OAS1 at the
position 347 in the 3'-UTR were estimated to be 41.7%
among European-Americans, 10.9% among African-
Americans, 18.2% among Japanese and 36.4% among
Chinese. The T allele frequencies of MxA at position 88 in
the promoter region were estimated to be 19.6% among
Caucasian and 33% among Vietnamese population. The
objective of the study was to investigate if single nucleic
acid polymorphisms (SNPs) of OAS1 and MxA genes were
associated with the development of SARS in Chinese Han
Population.
Methods
Cases and controls
A total of 66 confirmed SARS cases were included in the
study. All cases were Chinese Hans from a designated hos-
pital for SARS in Beijing. They were diagnosed according
to the criteria published by Chinese Ministry of Public
Health, and subsequently confirmed by serological test.
All the controls were also Chinese Han people. They were
healthy doctors and nurses working in the same hospital,
with a history of close contact with SARS patients. If a per-
son had shared a meal, utensil, residence, ward, vehicle
etc. with a SARS patient or visited a patient, a contact his-
tory of the person was realized. In addition, contagium
was also considered as close contact. All the controls were
negative for IgG antibody against SARS-CoV. Any controls
who are consanguineous with any cases were excluded.
Information collected using a questionnaire
A questionnaire was developed to collect information
from both cases and controls on demographic characteris-
tics (age, gender, region of origin, etc.), habits and medi-
cal history (smoking and drinking habit, diet, exercise,
medical history, history of operations, etc.), and protec-
tive measures (wearing masks, gowns and goggles when in
contact with SARS patients). All the cases and controls
filled in the questionnaire before providing 5 ml anti-
coagulated blood with EDTA. All participants signed an
informed consent. The study protocol was approved by
the ethical committee at National Center for AIDS Preven-
tion and Control.
DNA extraction
Leucocytes were isolated within 12 h of blood collection
using Percoll reagent. Then genomic DNA was extracted
using cell DNA extraction kit (BioDEV Inc. Beijing, China)
according to the manufacturer's instructions.
Genotyping of allelic variants of the OAS1 and MxA genes
The OAS1 gene's A/G SNP at the 3'UTR 347 locus of the
exon 8 (GenBank Acc No. M11810) was investigated in the
study. End-point real time PCR method was used in the
study. The Assays-on-Demand SNP Genotyping Products
kit was purchased from Applied Biosystems. Briefly, the
TaqMan Universal PCR Master Mix reagent containing a
pair of unlabeled primes and two allele-specific probes
were designed according to the SNP at 347 A/G 3' UTR of
the OAS1 gene (NCB1 SNP Acc No.r s2660). One probe
labeled FAM contains the A allele, and the other probe
labeled VIC contains G allele. PCR amplifications and flu-
orescent detections were performed in an ABI Prism
7900HT sequence detection system (ABI Ltd.). PCR mix-
ture in 25 µl volumes contained 20 ng genomic DNA, 2 ×
TaqMan Universal PCR Master Mix No AmpErase UNG
(12.5 µl), 20 × Assays-on-Demand SNP Genotyping Assay
Mix (1.25 µl). The cycling protocol was as follows: 10 min
at 95°C, followed by 40 cycles of 92°C for 15 s, 60°C for
1 min. The fluorescent signals were detected after the
amplification. The sample with high red fluorescent sig-
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nals was AA genotype, the sample with high green fluores-
cent signals was GG genotype, the sample with both high
fluorescent signals was AG genotype. Each sample was
detected two or three times.
The allelic G/T polymorphism in the promoter region of
MxA at position 88 from the transcription start site was
genotyped by PCR-restriction fragment length polymor-
phism (RFLP) method as previously described [16].
Amplification was carried out in a volume of 20 µl, con-
taining 10 – 100 ng DNA, 2.5 mM MgCl2, 500 nM of each
primer, 500 mM dNTP's, 1 × PCR buffer, 2 U Taq DNA
polymerase (Shanghai Sangon Biological engineering
technology and service Ltd., China). The cycling condi-
tions in an Applied Biosystems 2400 machine were: dena-
turation at 94°C for 5 min, subsequently 35 cycles of
denaturation at 94°C for 30 s; annealing at 58°C for 30 s;
and extension at 72°C for 1 min. This was followed by a
final extension at 72°C for 7 min. A total of 8 µl of the
PCR product was digested for 4 h in a volume of 20 µl
with 5 U HhaI according to the manufacturer's instruc-
tion. A volume of 10 µl digested PCR product was sepa-
rated on 2% agarose gels and visualized under ultraviolet
light. In the presence of the G allele, the 351-bp PCR prod-
uct was cut into 4 fragments (261, 51, 23 and 16 bp,
respectively), and in the presence of the T allele into 3
fragments (312, 23 and 16 bp, respectively).
Statistical analysis
Data were analyzed using the SPSS software (version 10.0,
SPSS Inc, Chicago, IL, USA). Unconditional logistic
regression was performed to estimate odds ratios (ORs)
and their 95% confidence intervals (CI). Univariate anal-
yses were conducted to determine the effect of each varia-
ble separately. Multivariate analyses were then performed
using genetic polymorphisms as independent variables
and all the significant variables in univariate analyses as
covariables. For all the analyses, statistical tests were based
on two-tailed probability. A P value <0.05 was considered
statistically significant.
Results
Demographic characteristics of cases and controls
A total of 66 cases and 64 controls were included in the
study. The mean age was 28.3 years for cases and 29.4
years for controls (P > 0.05). The proportion of males was
48.5% in cases and 68.8% in controls (P > 0.05).
Univariate analysis results of factors related to SARS
Several protection measures including wearing masks,
gowns and goggles were found to be significantly associ-
ated with decreased risk of SARS-CoV infection (P < 0.05).
No significant difference between cases and controls was
observed for the other factors, including smoking, alco-
hol-drinking, nutrition status and physical activities
(Table 1).
Univariate analysis results of OAS1 and MxA gene SNPs in 
relation to SARS
Allele frequencies of OAS1 and MxA genes in cases and
controls were compared (Table 2). The AG and GG geno-
types in the 3'UTR of the OAS1 gene were significantly less
frequent in case group (33.3% and 7.6%, respectively)
than in control group (48.4% and 15.6%, respectively).
Compared to AA genotype, AG and GG genotypes were
found associated with a protective effect on SARS with
ORs (95% CI) of 0.42 (0.20~0.89) and 0.30 (0.09~0.97),
respectively. Also, a GT genotype at position 88 in the
MxA gene promoter was associated with increased suscep-
tibility to SARS infection compared to a GG genotype (OR
= 3.06, 95% CI: 1.25~7.50).
Multivariate analysis results of OAS1 and MxA gene SNPs 
in relation to SARS
A multivariate analysis was conducted with disease status
as the dependent variable, each genotype as an independ-
ent variable, and wearing masks, gowns and goggle as cov-
ariables. It was indicated that the individuals with OAS1
AG genotype were at decreased risk, and those with MxA
genotype GT were at increased risk of contracting SARS
infection, as compared to AA and GG for OAS1 gene, and
to GG and TT for MxA gene, respectively (Table 3 and 4).
Discussion
Many factors may influence the outcome and clinical
manifestations of SARS infection, such as exposure levels,
differences in SARS-CoV strain virulence, host health sta-
tus, smoking, other virus co-infection, and host genetic
patterns. In order to study the association between gene
polymorphisms and SARS-CoV infection, we took several
measures to control for possible confounders. Firstly,
cases and controls were selected from the same hospital to
minimize the impact of virulence differences in SARS-CoV
strains. Secondly, each control had to have close contact
history with SARS patients to reduce differences in expo-
sure levels between cases and controls. Thirdly, multivari-
ate analyses were conducted to adjust the factors which
were statistically significant in univariate analyses. In fact,
mask-, gown- and goggles-wearing were found to be pro-
tective against SARS-CoV infection in this study as previ-
ously reported [18-20].
We found that both the AG and GG genotypes of OAS1
gene at the 3'-UTR region were more common among
controls compared to cases. The G allele frequency among
controls (39.8%) was comparable to that found in the 45
Han Chinese in Beijing. Our findings indicate that the G
allele in the OAS1 gene conferred protection against
SARS-CoV infection. Knapp reported that this A/G allele
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was associated with the outcome of HCV infection, OAS1
playing a greater role in mediating self-limiting versus per-
sistent HCV infection, rather than when viral persistence
is established [16]. A nonsense mutation described in the
gene encoding the mouse 2'-5' OAS1 isoform was associ-
ated with West Nile virus susceptibility in laboratory mice
[21,22]. There are two isoforms in human OAS1 gene
(E16 and E18), which share identical N-terminal
sequence but diverge at exon 7 [23]. Isoform E16 contains
7 exons and a hydrophobic C-terminus. Isoform E18 con-
tains an additional exon and is very hydrophilic as com-
pared to transcript variant E16. Production of the two
Table 2: Univariate analysis results of OAS1 AND MxA gene SNPs in cases and controls
Cases (%) Controls (%) OR (95% CI) P value
OAS1 3'-UTR
genotype 0.026
AA 39 (59.1) 23 (36.0) 1.00
AG 22 (33.3) 31 (48.4) 0.42 (0.20~0.89) 0.022
GG 5 (7.6) 10 (15.6) 0.30 (0.09~0.97) 0.038
allele
A 75.8 60.2
G 24.2 39.8
MxA -88
genotype 0.006
GG 13(19.7) 24(37.5) 1.00
GT 48(72.7) 29(45.3) 3.06(1.25~7.53) 0.006
TT 5(7.6) 11(17.2) 0.84(0.20~3.44) 0.784
allele
G 56.1 61.1
T 43.9 38.9
Table 1: Distribution of SARS-related factors in cases and controls
Variables Cases (%) Controls (%) P value
Wearing a mask 0.003
Always 38 (57.6) 54 (84.4)
Occasionally 12(18.2) 6(9.4)
Never 16(24.2) 4(6.2)
Wearing a gown <0.001
Always 21(31.8) 50(78.1)
Occasionally 2(3.0) 2(3.1)
Never 43(65.2) 12(18.8)
Wearing goggles <0.001
Always 18(27.3) 52(81.3)
Occasionally 7(10.6) 5(7.8)
Never 41(62.1) 7(10.9)
Smoking 0.434
Yes 7(11.1) 10(15.9)
No 56(88.9) 53(84.1)
Alcohol-drinking 0.914
Never 35(53.8) 33(53.2)
Occasionally 26(40.0) 24(38.7)
Often 4(6.2) 5(8.1)
Meat intake 0.616
Every day 34(51.5) 34(53.1)
Often 29(43.9) 29(45.3)
Rarely 3(4.6) 1(1.6)
Physical exercise 0.213
Rarely 18(28.1) 20(31.7)
1~2 times/week 27(42.2) 34(54.0)
>3 times/week 10(15.6) 5(7.9)
Every day 9(14.1) 4(6.4)
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mRNAs isoforms of OAS1 depends on processing that
involves the recognition site located within the 3'-termi-
nal exon [24]. The polymorphisms in the 3'UTR may be
related with the expression of the two isoforms. The
mechanisms of the protective effect of G allele need to be
elucidated.
Regarding the G/T polymorphism at position 88 in pro-
moter region of MxA gene, the GT genotype was found to
be more frequent in patients than in controls. Other
researchers found no difference in SARS-CoV replication
in Vero cells that were stably expressing MxA [25,26]. The
patients with GT genotype may express more MxA protein
when induced by IFNs. Consequently, the MxA protein
can promote the establishment of persistent SARS-CoV
infection. MxA protein may have dual functions in reac-
tion to virus infection. Torisu reported that T allele with a
high MxA-producing capability was more frequently seen
in subacute sclerosing panencephalitis (SSPE) patients
[27]. A luciferase reporter assay revealed that the MxA pro-
moter sequence of T haplotype had higher promoter activ-
ity than that of G haplotype [28]. Arcas et al. reported that
GT and TT genotype expressed higher amount of MxA
mRNA than GG genotype in IFN-treated peripheral blood
mononuclear cells in vitro [29]. In our study, 88 SNP in
MxA was related to disease susceptibility. The mechanism
of the MxA gene with SARS susceptibility needs to be fur-
ther investigated. Since the polymorphisms in the two
genes were associated with the SARS-CoV infection, we
tried to find out if combined action between mutations
could affect the susceptibility to SARS-CoV infection. But
the sample size of this study is not sufficient to do the
interaction analysis. More SARS cases and controls are
required to do so.
Table 4: Association between MxA genotypes and SARS infection after adjusting other related factors in multivariate analysis
Variable OR (95% CI) P value
Wearing a mask 0.100
Always 1.00
Occasionally 1.64(0.41~6.60) 0.486
Never 4.41(1.12~17.34) 0.034
Wearing a gown 0.753
Always 1.00
Occasionally 1.03 (0.10~10.75) 0.460
Never 1.63(0.45~6.01) 0.983
Wearing goggles 0.004
Always 1.00
Occasionally 3.48(0.77~15.80) 0.106
Never 9.51(2.34~38.73) 0.002
genotype 0.061
GG 1.00
GT 3.22 (1.13~9.18) 0.029
TT 1.17 (0.25~5.60) 0.843
Table 3: Association between OAS1 genotypes and SARS infection after adjusting other related factors in multivariate analysis
Variable OR (95% CI) P value
Wearing a mask 0.230
Always 1.00
Occasionally 1.70(0.42~6.86) 0.102
Never 3.11 (0.80~12.11) 0.456
Wearing a gown 0.490
Always 1.00
Occasionally 1.23 (0.13~11.62) 0.234
Never 2.19 (0.60~8.00) 0.857
Wearing goggles 0.006
Always 1.00
Occasionally 2.92(0.64~13.23) 0.002
Never 8.53 (2.16~33.73) 0.166
genotype 0.125
AA 1.00
AG 0.38(0.14~0.98) 0.047
GG 0.46(0.11~1.96) 0.291
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Conclusion
In conclusion, we showed that the SNPs in OAS1 and MxA
genes were associated with SARS-CoV infection in Chi-
nese Han population. These findings may lead to a better
understanding of IFN-induced antiviral response to SARS
infection.
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